Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 24, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• A total of 15,000 shares were sold in multiple transactions at weighted average prices ranging from $116.3275 to $119.013 per share.
• Following the reported transactions, Afeyan directly owns 2,239,015 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.
• He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a pre-planned sale of shares by a director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on material non-public information. The use of a 10b5-1 plan provides a legal framework for insiders to sell shares at predetermined times and prices.

Comparison to Industry Standards

• Comparing insider sales activity to peers like Pfizer (PFE) or BioNTech (BNTX) would require analyzing their respective SEC filings for similar Form 4 disclosures.
• Generally, insider selling can be compared to historical trends within the company and industry to assess whether the activity is unusual or consistent with past behavior.
• A large sale by a CEO would be viewed differently than a small sale by a director with limited operational involvement.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be minimal.

Key Dates